NCT06547151View on ClinicalTrials.gov

Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults

PHASE2RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Hypoparathyroidism
Interventions
DRUG

AMOR-1

Investigational arm: Tablets containing 250mg elemental calcium from Amorphous Calcium Carbonate (ACC).

DRUG

Crystalline Calcium Carbonate

Control arm: Crystalline Calcium Carbonate (CCC) oral tablet contains 500 mg elemental calcium.

Trial Locations (8)

49100

RECRUITING

Rabin Medical Center, Belinson Campus, Petah Tikva

Unknown

RECRUITING

Assuta Ashdod medical center, Ashdod

RECRUITING

Hadassah Ein Kerem Medical Center, Jerusalem

ACTIVE_NOT_RECRUITING

Barzilai Medical Center, Ashkelon

RECRUITING

Soroka Medical Center, Beersheba

NOT_YET_RECRUITING

Rambam Medical Center, Haifa

RECRUITING

Sheba Medical Center, Ramat Gan

NOT_YET_RECRUITING

Kaplan Medical Center, Rehovot

All Listed Sponsors
lead

Amorphical Ltd.

INDUSTRY